Mäenpää J, Kangas L, Grönroos M
Eur J Cancer Clin Oncol. 1985 Oct;21(10):1141-6. doi: 10.1016/0277-5379(85)90005-7.
The 6-day subrenal capsule assay (SRCA) in normal immunocompetent mice was used to assess response of vulvar and cervical cancers to chemotherapy. Twenty-five out of 31 assays (81%) were evaluable. The previously treated tumors tended to be less sensitive than the untreated tumors (20 vs 33%). Three to five cytotoxic drugs or drug combinations were tested against each individual tumor. In the whole material the combination of cisplatin and etoposide (VP-16) was significantly more effective than bleomycin (P less than 0.01, chi 2 test). The combinations adriamycin + cyclophosphamide + cisplatin and cyclophosphamide + methotrexate were also rather effective. Preliminary clinical correlations were positive. The reliability of the SRCA was discussed, and it was concluded that the assay is a promising predictive method for individualizing chemotherapy.
在正常免疫活性小鼠中进行为期6天的肾包膜下试验（SRCA），以评估外阴癌和宫颈癌对化疗的反应。31次试验中有25次（81%）可进行评估。先前接受过治疗的肿瘤往往比未治疗的肿瘤敏感性更低（20%对33%）。针对每个肿瘤测试了三到五种细胞毒性药物或药物组合。在整个研究材料中，顺铂和依托泊苷（VP-16）的组合明显比博来霉素更有效（P<0.01，卡方检验）。阿霉素+环磷酰胺+顺铂以及环磷酰胺+甲氨蝶呤的组合也相当有效。初步的临床相关性为阳性。讨论了SRCA的可靠性，得出的结论是该试验是一种有前景的用于个体化化疗的预测方法。
